Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
INO-A002
- Development stage
- Phase 1
- Lead developer
- Inovio Pharmaceuticals
- Modality
- DNA Vaccines → Plasmid DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Prophylactic Vaccines → Vaccines & Immunotherapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intramuscular
01
Overview
INO-A002 is a DNA-encoded monoclonal antibody (dMAb) developed for the prevention and treatment of Zika virus infection. The drug consists of a DNA plasmid encoding an anti-Zika virus monoclonal antibody, which is delivered intramuscularly using Inovio's proprietary CELLECTRA device. Once inside the body, the genetic instructions enable host cells to produce the therapeutic antibody *in vivo*, offering rapid and efficient production compared to traditional monoclonal antibodies. The mechanism of action includes stimulating immune responses such as antibody-dependent cell cytotoxicity and natural killer cell activation. INO-A002 represents a novel approach to passive immunization against infectious diseases by enabling direct *in vivo* expression of protective antibodies[1][2][3][4][6][8]. Developed by Inovio Pharmaceuticals and the University of Pennsylvania.
- Other names
- INO A002
02
Targets
ZIKV E (Zika virus envelope protein)
Beyond the preview
Go deeper on INO-A002.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on INO-A002.